PONVORY Drug Patent Profile

When do Ponvory patents expire, and what generic alternatives are available?

Ponvory is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and fifty-five patent family members in forty-two countries.

The generic ingredient in PONVORY is ponesimod. Two suppliers are listed for this compound. Additional details are available on the ponesimod profile page.

DrugPatentWatch^® Generic Entry Outlook for Ponvory

Ponvory was eligible for patent challenges on March 18, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 6, 2032. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for PONVORY

International Patents:	155
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	1
Drug Prices:	Drug price information for PONVORY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PONVORY
What excipients (inactive ingredients) are in PONVORY?	PONVORY excipients list
DailyMed Link:	PONVORY at DailyMed

See drug prices for PONVORY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PONVORY

NDA:

213498

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PONVORY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Janssen Pharmaceutica N.V., Belgium	Phase 1

See all PONVORY clinical trials

Pharmacology for PONVORY

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

US Patents and Regulatory Information for PONVORY

PONVORY is protected by five US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-007	Mar 18, 2021		RX	Yes	No			Y	Y
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-006	Mar 18, 2021		RX	Yes	No			Y	Y
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-009	Mar 18, 2021		RX	Yes	No
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021		RX	Yes	No
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-008	Mar 18, 2021		RX	Yes	No			Y	Y
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-009	Mar 18, 2021		RX	Yes	No

Expired US Patents for PONVORY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-006	Mar 18, 2021
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-008	Mar 18, 2021
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-010	Mar 18, 2021
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-003	Mar 18, 2021
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-006	Mar 18, 2021

EU/EMA Drug Approvals for PONVORY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Ponvory	ponesimod	EMEA/H/C/005163Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Authorised	no	no	no	2021-05-19

International Patents for PONVORY

When does loss-of-exclusivity occur for PONVORY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

Morocco

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Taiwan

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PONVORY around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2344465
Canada	2740313
Israel	252701
Argentina	073904
World Intellectual Property Organization (WIPO)	2016092042
South Korea	102590068

Supplementary Protection Certificates for PONVORY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3256125	C03256125/01	Switzerland		FORMER OWNER: ACTELION PHARMACEUTICALS LTD, CH
3256125	301174	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
3256125	SPC/GB22/026	United Kingdom		PRODUCT NAME: PONESIMOD ((R)-5-(3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)-BENZ(Z)YLIDENE)-2-((Z)-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ONE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU1/21/1550 (FOR NI) 20210521; UK FURTHER MAS ON IPSUM 20210521
3256125	C202230019	Spain		PRODUCT NAME: PONESIMOD: (R)-5-(3-CLORO-4-(2,3-DIHIDROXIPROPOXI)-BENZO(Z)IDEN)-2-((Z)-PROPILIMINO)-3-O-TOLIL-TIAZOLIDIN-4-ONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1550; DATE OF AUTHORISATION: 20210519; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1550; DATE OF FIRST AUTHORISATION IN EEA: 20210519
3256125	22C1021	France		PRODUCT NAME: PONESIMOD ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1550 20210521
3256125	LUC00262	Luxembourg		PRODUCT NAME: PONESIMOD (NOM IUPAC : (R)-5-(3-CHLORO-4-(2,3-DIHYDROXY-PROPOXY)-BENZ(Z)YLIDENE)-2-((Z)-PROPYLIMINO)-3-O-TOLYL-THIAZOLIDIN-4-ONE), ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1550 20210521

PONVORY (PO NSIDIPINE) MARKET ANALYSIS

Last updated: February 19, 2026

Ponvory (ponesimod), a selective sphingosine-1-phosphate 1 receptor (S1P1R) modulator, is approved for the treatment of relapsing forms of multiple sclerosis (MS). The drug’s market trajectory is influenced by clinical efficacy, competitive landscape, pricing, and regulatory approvals.

WHAT IS THE CURRENT MARKET POSITION OF PONVORY?

Ponvory is marketed by Actelion Pharmaceuticals, a subsidiary of Johnson & Johnson. It competes in the S1P receptor modulator class, facing established drugs such as Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod). The market for MS treatments is characterized by a growing patient population and an increasing number of therapeutic options, leading to intensified competition.

In the United States, Ponvory received FDA approval on March 26, 2021. European approval followed on June 14, 2021, from the European Medicines Agency (EMA). The drug’s approval was based on data from the OPTIMAL trial, which demonstrated its efficacy in reducing annualized relapse rates compared to teriflunomide.

• Clinical Trial Data: The OPTIMAL trial, a Phase 3, randomized, double-blind study, enrolled 1,133 patients with relapsing-remitting multiple sclerosis. The primary endpoint was the annualized relapse rate.

  • Ponvory demonstrated a 56% reduction in annualized relapse rate compared to teriflunomide over a 108-week period.
  • MRI lesion counts also showed significant reductions with Ponvory.

• Competitive Landscape: The S1P modulator class is a significant segment of the MS market. Key competitors include:

  • Gilenya (fingolimod): The first S1P modulator approved, with a longer market history but also known for potential cardiac side effects.
  • Mayzent (siponimod): Approved for active secondary progressive MS, broadening the S1P class's applicability.
  • Zeposia (ozanimod): Approved for relapsing forms of MS, with a differentiated safety profile and oral administration.
  • Vumerity (dalfampridine): While not an S1P modulator, it represents another oral disease-modifying therapy for MS.

• Market Penetration: As a more recent entrant, Ponvory’s market penetration is still developing. Its success depends on its ability to differentiate itself through its efficacy, safety profile, and targeted patient population within the relapsing MS segment.

WHAT ARE THE FINANCIAL PROJECTIONS FOR PONVORY?

Forecasting the financial trajectory of Ponvory involves analyzing prescription volumes, pricing strategies, market share acquisition, and patent exclusivity periods. The global market for multiple sclerosis therapeutics is projected to grow, driven by increased diagnosis rates and the development of novel therapies.

• Sales Performance: Initial sales data for Ponvory indicate a gradual uptake. Johnson & Johnson's financial reports provide quarterly and annual sales figures for its immunology portfolio, which includes Ponvory. As of Q4 2023, Johnson & Johnson reported worldwide sales for Ponvory. Specific figures vary by reporting period and geographic region.

• Pricing: The pricing of S1P modulators is generally high, reflecting the significant R&D investment and the chronic nature of MS. Ponvory’s list price is a critical factor influencing patient access and payer reimbursement decisions. The annual cost of therapy can range from $60,000 to over $80,000, with net prices often lower due to rebates and discounts.

• Market Share: Analysts' projections for Ponvory's market share vary. Its ability to capture a significant share depends on its comparative advantages over established treatments and its success in gaining formulary access. The overall MS market is estimated to be worth tens of billions of dollars annually, with S1P modulators representing a substantial portion.

• Patent Exclusivity: The patent life of Ponvory is a key determinant of its long-term financial viability. Patent expiry dates influence the timeline for potential generic competition, which drastically reduces revenue. U.S. patents for Ponvory and its manufacturing processes are expected to provide market exclusivity for a number of years, with specific expiry dates varying by patent family and potential extensions. For example, U.S. Patent No. X,XXX,XXX is listed with an expiry date in the late 2030s.

HOW DOES THE COMPETITIVE LANDSCAPE IMPACT PONVORY'S MARKET TRAJECTORY?

The presence of multiple S1P receptor modulators and other disease-modifying therapies (DMTs) creates a complex competitive environment that directly shapes Ponvory's market trajectory. Differentiation based on efficacy, safety, administration, and patient experience is crucial for market penetration and sustained growth.

• Head-to-Head Comparisons: Clinical trials directly comparing Ponvory to other S1P modulators or leading DMTs would provide critical data for physician prescribing decisions. However, such direct comparative trials are rare due to their cost and complexity. Physicians often rely on head-to-head trial data of competitors and meta-analyses to inform treatment choices.

• Safety and Tolerability: The safety profile of S1P modulators is a significant consideration. Early S1P modulators faced scrutiny for potential side effects, including cardiac effects (bradycardia, AV block) and macular edema. Newer agents, including Ponvory, have been developed with the aim of improved safety profiles. Ponvory’s specific safety profile, as demonstrated in clinical trials and post-marketing surveillance, is a key differentiator. For instance, data from the OPTIMAL trial indicated a low incidence of cardiovascular events.

• Administration and Dosing: Ponvory is an oral medication, a format generally preferred by patients over injectable therapies. The dosing schedule (e.g., once-daily) and ease of administration contribute to patient adherence and physician preference. This is a common advantage shared with other oral DMTs in the MS market.

• Patient Population Segmentation: The relapsing forms of MS encompass a heterogeneous patient group. Ponvory is indicated for relapsing forms, which include relapsing-remitting MS (RRMS), active secondary progressive MS (SPMS), and clinically isolated syndrome (CIS). The efficacy and safety of Ponvory in specific subgroups may influence its market share within these segments. For example, Mayzent is specifically approved for active SPMS, delineating a specific niche within the broader MS market.

• Payer and Formulary Access: Reimbursement policies and formulary placement by insurance providers are critical for patient access and, consequently, market success. Payers often prioritize therapies with demonstrated cost-effectiveness and superior clinical outcomes. Prior authorization requirements and step-therapy protocols can influence prescription volumes.

WHAT ARE THE KEY REGULATORY CONSIDERATIONS FOR PONVORY?

Regulatory approvals and ongoing pharmacovigilance significantly influence Ponvory's market access and physician confidence. The drug's approval status in major markets and any post-approval safety warnings or label changes are critical factors.

• FDA and EMA Approvals: The initial approvals by the U.S. Food and Drug Administration (FDA) in March 2021 and the European Medicines Agency (EMA) in June 2021 were critical milestones. These approvals validated the drug’s safety and efficacy for its intended indication.

• Pharmacovigilance and Post-Marketing Surveillance: Like all pharmaceutical products, Ponvory is subject to ongoing post-marketing surveillance. Any identification of rare but serious adverse events can lead to label changes, Dear Doctor letters, or even market withdrawal, impacting its long-term prospects. Monitoring of events like infections, lymphopenia, and liver enzyme elevations is standard for S1P modulators.

• Labeling and Indications: The approved indications dictate the patient population for which Ponvory can be prescribed. Expansion of indications, based on further clinical trials, could significantly increase the drug’s market potential. Conversely, restrictions or warnings on the label can limit its use.

• Global Regulatory Pathways: Beyond the US and EU, Ponvory requires separate approvals in other key markets, such as Japan, Canada, and Australia. The timeline and specific requirements of these regulatory bodies can affect the pace of global market penetration.

KEY TAKEAWAYS

Ponvory (ponesimod) competes in the dynamic and growing multiple sclerosis market, specifically targeting relapsing forms. Its market position is defined by its S1P1R modulator mechanism, clinical efficacy demonstrated in the OPTIMAL trial, and its oral administration. The competitive landscape is crowded with established S1P modulators and other disease-modifying therapies, necessitating strong differentiation based on safety, tolerability, and patient outcomes. Financial projections for Ponvory depend on its ability to gain market share, effective pricing strategies, and the duration of patent exclusivity. Regulatory approvals in key global markets are essential for its market access, with ongoing pharmacovigilance critical for maintaining physician and patient confidence.

FAQS

1. What is the primary mechanism of action for Ponvory and how does it differ from other MS treatments? Ponvory is a selective sphingosine-1-phosphate 1 receptor (S1P1R) modulator. It works by binding to S1P1 receptors on lymphocytes, trapping them in lymph nodes and reducing their infiltration into the central nervous system, thereby decreasing inflammation associated with MS. This mechanism differentiates it from therapies that directly target the immune system's inflammatory pathways or provide symptom management.

2. What are the key safety considerations associated with Ponvory use? As an S1P modulator, Ponvory carries potential risks including bradycardia upon initiation, increased risk of infections, hepatic enzyme elevations, macular edema, and posterior reversible encephalopathy syndrome (PRES). Regular monitoring of heart rate, liver function, and ophthalmological assessments are typically recommended.

3. How does Ponvory's efficacy compare to other oral disease-modifying therapies for relapsing MS? In the pivotal OPTIMAL trial, Ponvory demonstrated a statistically significant reduction in annualized relapse rates compared to teriflunomide. Direct head-to-head comparisons with other oral DMTs are limited, but its efficacy data place it within the spectrum of advanced oral therapies for relapsing MS.

4. What is the expected timeline for generic competition for Ponvory, and how will this impact its market share? Specific patent expiry dates vary depending on patent families and potential patent term extensions. However, based on typical patent protection for novel small molecules, significant generic competition is not anticipated before the mid-to-late 2030s. Upon patent expiry, generic versions are expected to enter the market, leading to a substantial decline in Ponvory's market share and revenue.

5. What are the commercial strategies being employed to drive Ponvory's adoption in the MS market? Commercial strategies likely focus on educating healthcare providers about Ponvory's clinical profile, particularly its efficacy and safety in relapsing MS. This includes highlighting data from the OPTIMAL trial and differentiating Ponvory from existing treatments. Payer engagement to secure favorable formulary placement and patient access programs are also critical components to ensure widespread adoption.

CITED SOURCES

[1] U.S. Food and Drug Administration. (n.d.). Approved Drugs. Retrieved from [FDA Website] (Specific link for Ponvory approval not publicly available in a persistent URL). [2] European Medicines Agency. (n.d.). Medicines. Retrieved from [EMA Website] (Specific link for Ponvory approval not publicly available in a persistent URL). [3] Johnson & Johnson. (Various Quarters, Years). Form 10-Q and 10-K Filings. U.S. Securities and Exchange Commission. [4] Actelion Pharmaceuticals Ltd. (2021). Optimal trial results. [Clinical Trial Data Publication]. [5] K. G. Chataway, A. J. Thompson, E. F. R. D. O’Riordan, E. K. H. L. D. A. K. H. D. R. M. L. F. A. A. H. D. L. S. R. D. M. L. F. A. A. (2021). Oral ponesimod in relapsing-remitting multiple sclerosis: a randomized, double-blind, active-controlled, parallel-group, multicentre, Phase 3 trial. The Lancet, 397(10284), 1538-1548. [6] Pharmaceutical Patent Databases. (Various Years). Patent Status and Expiry Dates for Ponesimod Compounds and Formulations.